<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">109609</article-id><article-id pub-id-type="doi">10.26442/00403660.2022.06.201562</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical significance of serum levels of osteoproteherin and sclerostin in assessment of vascular calcification in chronic kidney disease stage 3–5</article-title><trans-title-group xml:lang="ru"><trans-title>Клиническое значение сывороточных концентраций остеопротегерина и склеростина в оценке сосудистой кальцификации при хронической болезни почек С3–С5Д стадии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7314-9063</contrib-id><name-alternatives><name xml:lang="en"><surname>Dzgoeva</surname><given-names>Fatima U.</given-names></name><name xml:lang="ru"><surname>Дзгоева</surname><given-names>Фатима Урузмаговна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. внутренних болезней №5</p></bio><email>fdzgoeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4175-5365</contrib-id><name-alternatives><name xml:lang="en"><surname>Remizov</surname><given-names>Oleg V.</given-names></name><name xml:lang="ru"><surname>Ремизов</surname><given-names>Олег Валерьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. лучевой диагностики с лучевой терапией и онкологией</p></bio><email>fdzgoeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0539-8666</contrib-id><name-alternatives><name xml:lang="en"><surname>Botcieva</surname><given-names>Victoria Kh.</given-names></name><name xml:lang="ru"><surname>Боциева</surname><given-names>Виктория Хадзибатровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант каф. биохимии</p></bio><email>fdzgoeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5310-889X</contrib-id><name-alternatives><name xml:lang="en"><surname>Goloeva</surname><given-names>Victoria G.</given-names></name><name xml:lang="ru"><surname>Голоева</surname><given-names>Виктория Герсановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант каф. внутренних болезней №5</p></bio><email>fdzgoeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5564-9948</contrib-id><name-alternatives><name xml:lang="en"><surname>Malakhova</surname><given-names>Nina G.</given-names></name><name xml:lang="ru"><surname>Малахова</surname><given-names>Нина Геннадиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант каф. акушерства и гинекологии №1</p></bio><email>fdzgoeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4183-2335</contrib-id><name-alternatives><name xml:lang="en"><surname>Ikoeva</surname><given-names>Zarina R.</given-names></name><name xml:lang="ru"><surname>Икоева</surname><given-names>Зарина Руслановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант каф. внутренних болезней №5</p></bio><email>fdzgoeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">North Ossetian State Medical Academy</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-08-04" publication-format="electronic"><day>04</day><month>08</month><year>2022</year></pub-date><volume>94</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>731</fpage><lpage>737</lpage><history><date date-type="received" iso-8601-date="2022-08-04"><day>04</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-04"><day>04</day><month>08</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/109609">https://ter-arkhiv.ru/0040-3660/article/view/109609</self-uri><abstract xml:lang="en"><p><bold>Aim. </bold>To clarify the mechanisms of the effect of osteoprotegerin (OPG) and sclerostin on vascular calcification and the state of the cardiovascular system in chronic kidney disease (CKD).</p> <p><bold>Materials and methods. </bold>A total of 110 patients aged 18 to 65 years with CKD stages 3–5D were examined. OPG, sclerostin, intact parathyroid hormone, and serum troponin I were determined using the commercial "Enzyme-linked Immunosorbent Assay Kit for Sclerostin" from Cloude-Clone Corp. (USA) by enzyme-linked immunosorbent assay.</p> <p><bold>Results. </bold>An increase in sclerostin and OPG levels was revealed, which significantly correlated with a decrease in glomerular filtration rate, as well as an increase in left ventricle myocardial mass index and peak systolic blood flow in the aortic arch.</p> <p><bold>Conclusion. </bold>Changes in the regulation of bone-mineral metabolism, in which the proteins inhibitors of bone metabolism, OPG and sclerostin, as well as the interactive interaction between the vascular and skeletal systems, play a decisive role in the development of lesions of the cardiovascular system caused by vascular calcification in CKD.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель. </bold>Уточнить механизмы влияния остеопротегерина (ОПГ) и склеростина на процессы кальцификации сосудов и состояние сердечно- сосудистой системы при хронической болезни почек (ХБП).</p> <p><bold>Материалы и методы. </bold>Обследованы 110 пациентов в возрасте от 18 до 65 лет, страдающих ХБП С3–С5Д. ОПГ, склеростин, интактный паратгормон, тропонин I в сыворотке крови определяли с использованием коммерческих наборов «Enzyme-linked Immunosorbent Assay Kit for Sclerostin» (Cloude-Clone Corp., США) методом иммуноферментного анализа.</p> <p><bold>Результаты. </bold>Установлено повышение содержания склеростина и ОПГ, статистически значимо коррелирующее со снижением скорости клубочковой фильтрации, а также с увеличением индекса массы миокарда левого желудочка и пиковой систолической скоростью кровотока в дуге аорты.</p> <p><bold>Заключение. </bold>Изменения в регуляции костно-минерального обмена, в котором участвуют белки-ингибиторы костного метаболизма ОПГ и склеростин, а также интерактивное взаимодействие между сосудистой и скелетной системами играют решающую роль в развитии поражений сердечно-сосудистой системы, обусловленных сосудистой кальцификацией при ХБП.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic kidney disease</kwd><kwd>osteoprotegerin</kwd><kwd>sclerostin</kwd><kwd>cardiovascular calcification</kwd><kwd>remodeling of the heart and aorta</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>остеопротегерин</kwd><kwd>склеростин</kwd><kwd>кардиоваскулярная кальцификация</kwd><kwd>ремоделирование сердца и аорты</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Pereira L, Frazão JM. The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine. Clin Chim Acta. 2020;508:221-27. DOI:10.1016/j.cca.2020.05.023</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Sieklucka B, Domaniewski T, Zieminska M, et al. Сorrelation between OPG/RANKL/RANK axis, vitaminD status, PTH and vascular calcification in the adenin-indused model of chronic kidney Disease. Nephrol Dial Transplant. 2020;35(Suppl. 3):gfaa142.P0690. DOI:10.1093/ndt/gfaa142.P0690</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Rochette L, Meloux A, Rigal E, et al. The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics. Calcif Tissue Int. 2019;105(3):239-51. DOI:10.1007/s00223-019-00573-6</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Drechsler C, Evenepoel P, Vervloet MG, et al. NECOSAD Study Group. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2015;30(2):288-93. DOI:10.1093/ndt/gfu301</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Palmer SC, Teixeira-Pinto A, Saglimbene V, et al. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis. Am J Kidney Dis. 2015;66(6):962-71. DOI:10.1053/j.ajkd.2015.03.036</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wu J, Li X, Gao F, et al. Osteoprotegerin SNP associations with coronary artery disease and ischemic stroke risk: a meta-analysis. Biosci Rep. 2020;40(10):BSR20202156. DOI:10.1042/BSR20202156</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Дзгоева Ф.У., Сопоев М.Ю., Саламова Э.Э., и др. Остеопротегерин и RANKL: роль в развитии сердечно-сосудистых осложнений у больных с терминальной стадией почечной недостаточности, получающих гемодиализ. Нефрология. 2017;21(5):28-35 [Dzgoeva FU, Sopoev MYu, Salamova EE, et al. Osteoprotegerin and RANKL: a role in the development of cardiovascular complications in patients with terminal stage of renal failure receiving hemodialysis. Nephrology (Saint-Petersburg). 2017;21(5):28-35 (in Russian)]. DOI:10.24884/1561-6274-2017-21-5-28-35</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Stavrinou E, Sarafidis PA, Koumaras C, et al. Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects. Kidney Blood Press Res. 2019; 44(4):679-89. DOI:10.1159/000501205</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Claes KJ, Viaene L, Heye S, et al. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013;98:3221-8. DOI:10.1210/jc.2013-1521</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6(4):877-82. DOI:10.2215/CJN.06550810</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Pelletier S, Dubourg L, Carlier MC, et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):819-23. DOI:10.2215/CJN.07670712</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Thambiah S, Roplekar R, Manghat P, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90(6):473-80. DOI:10.1007/s00223-012-9595-4</mixed-citation></ref></ref-list></back></article>
